AI in myeloproliferative neoplasms can grade marrow fibrosis and predict survival, but authors say prospective, outcome-focused trials are needed first.
|Videos|October 29, 2014
Dr Chris Carroll Expounds the Risk of Avoiding Social Media
Fear is the biggest barrier preventing providers from using social media to its fullest potential, according to Christopher Carroll, MD, social media editor at CHEST and research director for the Division of Critical Care at the Connecticut Children's Medical Center.
Advertisement
Fear is the biggest barrier preventing providers from using social media to its fullest potential, according to Christopher Carroll, MD, social media editor at CHEST and research director for the Division of Critical Care at the Connecticut Children’s Medical Center.
At the 2014 CHEST meeting in Austin, Texas, Dr Carroll explained the real risks facing providers who use social media inappropriately.
“But there is also a risk of not participating in social media,” he said. “Because even if you’re not on social media, there are others who might be talking about you.”
Advertisement
Related to this article
Costs of multimorbidity in older adults are climbing faster than its disability toll, and study authors say policy should look past single-disease programs.
Kidney Week 2026 brought strong IgAN data, looked back on 5 years of value-based kidney care, and highlighted evidence of persistent CKD care gaps.
Norah Terrault, MD, MPH, on why few diagnosed patients reach HCV cure and how primary care test-and-treat can close the gap.
An analysis of AccessHope case reviews found that experts recommended changes in more than 80% of cases. About half were implemented, saving a median of $18,636 per case.
Early modeling put sickle cell gene therapy coverage near 11 cents per member per month.
At an AJMC® Stakeholder Interchange in Los Angeles, leukemia specialists described a region where hospital formularies push menin inhibitor starts into the clinic, emergency department (ED) physicians may not recognize differentiation syndrome, and capitated insurance contracts steer some patients with acute myeloid leukemia away from academic centers.
At AMCP Nexus 2026, payers said evidence, differentiation, and delivery now matter as much as FDA approval.
Advertisement
Advertisement
Trending on AJMC
1
Four Major Idiopathic Pulmonary Fibrosis Advances From 2026
2
Disability, Economic Toll of Multimorbidity Climb in Older Adults
3
October FDA Approvals Bring Advances Across 5 Specialties
4
HHS Draft Policy Eases Enforcement on 6 Compounded Peptides
5